Early Detection of Multiple Myeloma to Fight Cancer Disparities: A Screening and Patient Navigation Program

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

NA

Total Enrollment

201 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-06-16

Study Completion Date

2026-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This project will pilot the expansion of the existing Taussig Outreach Program's community outreach and patient navigation model to study the multiple myeloma (MM) screening program. This involves analyzing community reception, screening program methods, reasons patients decided to participate, reasons patients declined participation, and participant views and attitudes. This study also aims to gauge the current and general understanding of MM. This study seeks to recruit participants in the pilot screening program to promote early detection. Participants who have abnormal results will receive patient navigation for further diagnostics and testing.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Assessment of Early Detection and Prognosis Based on cfDNA Methylation in Multiple Myeloma

NCT05693012

Multiple Myeloma

UNKNOWN

Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile

NCT01454297

Multiple Myeloma

COMPLETED

Predicting Progression of Developing Myeloma in a High-Risk Screened Population

NCT05837884

Healthy

RECRUITING NA

The Aim is to Identify Recurrent Genomic Mutations and/or Predisposing Polymorphisms in Patients With Sporadic Cases of Multiple Myeloma

NCT05331313

Multiple Myeloma

UNKNOWN

Observational Prospective Research Study In Monoclonal Gammopathies leadINg to Myeloma

NCT02726750

Monoclonal Gammopathy of Undetermined Significance Smoldering Plasma Cell Myeloma

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Multiple Myeloma (MM) is a hematologic cancer of antibody-producing plasma cells. Multiple Myeloma is always preceded by a pre-malignant condition called monoclonal gammopathy of undetermined significance (MGUS) or smoldering multiple myeloma. Despite multiple therapeutic advances, there remains no cure for multiple myeloma. The disease is treated and monitored throughout a person's lifetime. This is why screening for early detection of this disease is important; however, MGUS and smoldering multiple myeloma are only diagnosed when they are found incidentally on labs during tests for unrelated symptoms. There are no current universal screening guidelines for MM. Among those who may benefit from MM screenings include African American/Black individuals, as it is twice as common in this population compared to Caucasian/White individuals. This study aims to develop a screening program specifically targeting underserved African American/Black individuals. This project will expand the existing Taussig Community Outreach screening program to include screening for multiple myeloma.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Multiple Myeloma Monoclonal Gammopathy of Undetermined Significance Smoldering Multiple Myeloma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Not a randomized trial; use of convenience sampling.

Primary Study Purpose

SCREENING

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Multiple Myeloma Screening Experience

Participants will partake in a multiple myeloma screening program. The screening involves a blood sample and the completion of a questionnaire to gauge participants' multiple myeloma knowledge.

Group Type EXPERIMENTAL

Multiple Myeloma M-Protein Analysis

Intervention Type OTHER

Participants will be screened with a blood test for monoclonal protein analysis

Multiple Myeloma Knowledge Questionnaires

Intervention Type OTHER

Participants will complete two questionnaires to share their attitudes toward their screening experience and completion of knowledge questions to gauge community reception and participant multiple myeloma knowledge.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Multiple Myeloma M-Protein Analysis

Participants will be screened with a blood test for monoclonal protein analysis

Intervention Type OTHER

Multiple Myeloma Knowledge Questionnaires

Participants will complete two questionnaires to share their attitudes toward their screening experience and completion of knowledge questions to gauge community reception and participant multiple myeloma knowledge.

Intervention Type OTHER